Glaxo antibody treatment works on Omicron mutations in study

play article
Subscribers can listen to this article

GlaxoSmithKline has said research shows its Covid-19 antibody treatment is effective against the full combination of mutations in the new Omicron variant.

Tests done in-vitro against a pseudo-virus that recreates a synthesised version of Omicron showed that sotrovimab, Glaxo’s antibody treatment, stands up to all mutations in the spike protein of the omicron variant and not just the key mutations, the drugmaker said in a statement on Tuesday. The tests included all 37 mutations identified to-date in the spike protein. 

Shares of Vir Biotechnology, the drug’s co-developer, were up as much as 7.4% in pre-market trading. Glaxo rose 0.5% in London after a study showed that the UK drugmaker’s vaccine developed with Medicago showed efficacy against several variants of Covid-19.

Glaxo’s observations come amid uncertainty about whether omicron erodes the defences of existing medicines and vaccines — and by how much. Its many mutations, particularly on the spike protein that’s the target of most treatments, have sparked concern worldwide and spooked financial markets. 

Given the less than three-fold drop in neutralisation during tests, “we are confident that sotrovimab will continue to provide significant benefit for the early treatment of patients hoping to avoid the most severe consequences of Covid-19,” said Vir Chief Executive Officer George Scangos.

Sotrovimab reduced the risk of hospitalisation and death in people with mild to moderate Covid by 79% in trials. The drug won clearance from UK regulators this month.

“The 3-fold reduction in sotrovimab’s ability to neutralise omicron in analysis conducted by GlaxoSmithKline’s partner Vir Biotechnology should still mean a substantial level of efficacy vs. the variant — though we have yet to see the details — especially given the potential to dose at higher levels if needed. We continue to expect that the drop in activity for sotrovimab — and that of AstraZeneca’s AZD7442 — will be less severe than that of Eli Lilly-AbCellera and Roche-Regeneron’s antibodies. Glaxo’s 750 000 doses in committed contracts with various governments could equate to $1.5 billion of sales.”
-John Murphy, BI pharmaceuticals analyst

Glaxo said last week the drug was effective against key mutations in omicron but the more recent tests provide more certainty it could hold up against the variant.

The injected antibodies are just one tool in the arsenal of Covid-19 treatments, but they could be the key for immune-suppressed people who don’t mount an adequate response to vaccines and help lessen the effects of the virus in those more susceptible to severe disease.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Rand - Dollar
Rand - Pound
Rand - Euro
Rand - Aus dollar
Rand - Yen
Brent Crude
Top 40
All Share
Resource 10
Industrial 25
Financial 15
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot